Quantifying Morbidity Risk Attributed to Red‐Cell Transfusion Volume in Optimally Transfused Patients With β‐Thalassemia
American Journal of Hematology · 2026
DOI: 10.1002/ajh.70100 ↗Kurz gefasst
Leserbrief in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Khaled M Musallam und 19 weiteren Autor:innen. Beteiligte Einrichtung: Center for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Medical City, Abu Dhabi, UAE. Hauptthemen laut MEDLINE: beta-Thalassemia, Erythrocyte Transfusion. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: Agios Pharmaceuticals Inc., Agios Pharmaceuticals.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Medical City, Abu Dhabi, UAE.
- Department of Public Health & Epidemiology, Khalifa University, Abu Dhabi, UAE.
- Division of Hematology/Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, New York, USA.
- Campus of Haematology Franco and Piera Cutino, UOC Ematologia per le Malattie Rare Del Sangue e degli Organi Ematopoietici, AOOR Villa Sofia-V. Cervello, Palermo, Italy.
- Laboratorio Biobanca, UOC Ematologia per le Malattie Rare Del Sangue e degli Organi Ematopoietici, Palermo, Italy.
- UOSD Diagnostica Molecolare Malattie Rare Ematologiche, AOOR Villa Sofia-Cervello, Palermo, Italy.
ORCID-Profile: Khaled M Musallam, Angela Vitrano, Rosario Di Maggio, Maria Concetta Renda, Antonino Giambona, Efthymia Vlachaki, Paolo Ricchi, Filomena Longo, Aurelio Maggio
Förderung
- Agios Pharmaceuticals Inc.
- Agios Pharmaceuticals
Zitieren
APA
Musallam, K. M., Vitrano, A., Inzerillo, A., Di Maggio, R., Barone, R., Giangreco, A., Renda, M. C., Fecarotta, E., Troia, A., Giambona, A., Ruffo, G. B., Vlachaki, E., Venou, T. M., Ricchi, P., Ziello, B., Serra, M., Colizzi, E., Longo, F., Culcasi, M., & Maggio, A. (2026). Quantifying Morbidity Risk Attributed to Red‐Cell Transfusion Volume in Optimally Transfused Patients With β‐Thalassemia. American Journal of Hematology. https://doi.org/10.1002/ajh.70100
Vancouver
Musallam KM, Vitrano A, Inzerillo A, Di Maggio R, Barone R, Giangreco A, et al. Quantifying Morbidity Risk Attributed to Red‐Cell Transfusion Volume in Optimally Transfused Patients With β‐Thalassemia. American Journal of Hematology. 2026. doi:10.1002/ajh.70100
BibTeX
@article{Musallam2026,
author = {Musallam, Khaled M and Vitrano, Angela and Inzerillo, Alessandro and Di Maggio, Rosario and Barone, Rita and Giangreco, Antonino and Renda, Maria Concetta and Fecarotta, Emanuela and Troia, Antonio and Giambona, Antonino and Ruffo, Giovan Battista and Vlachaki, Efthymia and Venou, Theodora M and Ricchi, Paolo and Ziello, Brunella and Serra, Marilena and Colizzi, Elena and Longo, Filomena and Culcasi, Martina and Maggio, Aurelio},
title = {Quantifying Morbidity Risk Attributed to Red‐Cell Transfusion Volume in Optimally Transfused Patients With β‐Thalassemia},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70100}
}
EUVIMED